血管紧张素转换酶抑制剂对阻塞性睡眠呼吸暂停低通气综合征合并高血压患者睡眠呼吸障碍干预效应的研究  

Effects of angiotensin converting enzyme inhibitors on apnea and hypopnea in patients with obstructive sleep apnea-hypopnea syndrome complicated by hypertension

作　　者：毕小瑞[1] 张立强[1] 姚婉贞[1] 王建丽[1] 任斌[1] 王玉柱[1] 贺蓓[1] 

机构地区：[1]北京大学第三医院呼吸科,100191

出　　处：《国际呼吸杂志》2011年第7期503-506,共4页International Journal of Respiration

摘　　要：目的 研究血管紧张素转换酶抑制剂（ACEI）对于阻塞性睡眠呼吸暂停低通气综合征（OSAHS）合并高血压患者睡眠呼吸障碍的干预效应.方法 63例经多导睡眠图证实的OSAHS患者被纳入本研究（男54例,女9例）,平均年龄（53±12）岁,按照其病情和服药情况分为3组,OSAHS无高血压组（A组）21例,OSAHS合并高血压未服降压药组（B组）19例,OSAHS合并高血压服用ACEI类降压药组（C组）23例.比较三组患者睡眠呼吸暂停低通气指数（AHI）,睡眠时最低血氧饱和度（LSaO2）.结果 C组患者AHI明显低于B组[（21,32±3.53）次/h vs（38.99±2.51）次/h,P＜0.05],LSaO2明显高于B组[（79.43士7.54）%vs（72.56±10.5）%,P＜0.05];C组和A组AHI和LSaO2差异无统计学意义（P＞0.05）.结论 ACEI类降压药可能具有改善OSAHS合并高血压患者睡眠呼吸障碍的效应.Objective To investigate the effects of angiotensin converting enzyme inhibitors （ACEI） on apnea and hypopnea in patients with obstructive sleep apnea-hypopnea syndrome（OSAHS）complicated by hypertension. Methods 63 subjects with OSAHS examined by polysomnography （PSG）were enrolled in this study （male 54, female 9）, average age （ 53 ± 12 ） years. The subjects were divided into 3 groups, group A（pure OSAHS group, n = 21）, group B（hypertension patients with OSAHS without antihypertensive treatment group, n = 19）, group C（hypertension patients with OSAHS with ACEI group, n =23）. All subjects underwent 8-hour PSG monitoring and their data were analyzed. The apnea-hypopnea index （AHI） and lowest SaO2 （LSaO2） were compared among the three groups. Results The AHI of group C were lower significantly than that of group B [（21. 32±3. 53） n/h vs （38. 99±2.51） n/h,P 〈0. 05], while LSaO2 of group C were higher significantly than that of group B [（79. 43±7. 54） % vs（72.56±10. 5） %, P 〈0.05]. There was no significant difference in AHI and LSaO2 between group A and group C. Conclusions ACEI may have improving effects on apnea and hypopnea in hypertension patients with OSAHS.

关 键 词：阻塞性睡眠呼吸暂停低通气综合征 血管紧张素转换酶抑制剂 呼吸暂停 低通气 

分 类 号：R766[医药卫生—耳鼻咽喉科]